Rocket Pharmaceuticals Inc
RCKT3.170USD
-0.060-1.86%
收盘 11/07, 16:00（美东）报价延迟15分钟
343.02M总市值
亏损市盈率 TTM
关于 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的后期生物技术公司。该公司正在推进一系列可持续的试验性基因疗法，旨在纠正复杂和罕见疾病的根本原因。其基于慢病毒 (LV) 载体的基因疗法针对血液病，包括针对范康尼贫血症（一种难以治疗的遗传病，会导致骨髓衰竭和潜在的癌症）、白细胞粘附缺陷-I (LAD-I)（一种严重的儿科遗传病，会导致反复发作且危及生命的感染，这些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一种单基因红细胞疾病，导致红细胞破坏增加和轻度至危及生命的贫血）的后期项目。该公司还有两个临床阶段和一个临床前阶段的体内腺相关病毒 (AAV) 项目，包括针对 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 扩张型心肌病的项目。
Rocket Pharmaceuticals Inc简介
公司代码RCKT
公司名称Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
员工数量299
证券类型Ordinary Share
年结日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编08512
电话16464409100
网址https://www.rocketpharma.com/
公司代码RCKT
上市日期Feb 18, 2015
CEODr. Gaurav D. Shah, M.D.
Rocket Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
60.82K
-32.22%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Independent Director
Independent Director
40.00K
+33.33%
Dr. Fady Ibraham Malik, M.D., Ph.D.
Dr. Fady Ibraham Malik, M.D., Ph.D.
Independent Director
Independent Director
30.00K
--
Mr. Carsten Boess
Mr. Carsten Boess
Independent Director
Independent Director
30.00K
--
Mr. Piratip Pratumsuwan
Mr. Piratip Pratumsuwan
Independent Director
Independent Director
30.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Head of Research and Development
President, Head of Research and Development
513.63K
-0.42%
Mr. Christopher Stevens
Mr. Christopher Stevens
Chief Operating Officer
Chief Operating Officer
407.17K
--
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
125.12K
+31.54%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
60.82K
-32.22%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
44.22K
+210.97%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 14 小时前
更新时间: 14 小时前
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.89%
Suvretta Capital Management, LLC
3.84%
其他
59.76%
持股股东
持股股东
占比
RTW Investments L.P.
16.39%
Maverick Capital, Ltd.
7.75%
The Vanguard Group, Inc.
6.37%
BlackRock Institutional Trust Company, N.A.
5.89%
Suvretta Capital Management, LLC
3.84%
其他
59.76%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
29.89%
Hedge Fund
28.47%
Investment Advisor
23.23%
Research Firm
6.15%
Individual Investor
3.80%
Bank and Trust
0.28%
Venture Capital
0.14%
Pension Fund
0.13%
Family Office
0.04%
其他
7.88%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
493
95.29M
88.31%
-15.26M
2025Q2
493
101.52M
94.23%
-15.02M
2025Q1
494
114.28M
106.44%
-9.69M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
17.69M
16.39%
--
--
Sep 19, 2025
Maverick Capital, Ltd.
8.36M
7.75%
+2.82M
+50.78%
Jun 30, 2025
The Vanguard Group, Inc.
6.10M
5.65%
-502.58K
-7.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.35M
5.89%
+202.53K
+3.29%
Jun 30, 2025
Suvretta Capital Management, LLC
4.14M
3.84%
+641.33K
+18.31%
Jun 30, 2025
MPM BioImpact LLC
3.90M
3.62%
+2.28M
+141.19%
Jun 30, 2025
Two Sigma Investments, LP
3.23M
2.99%
+3.23M
--
Jun 30, 2025
Millennium Management LLC
2.35M
2.18%
+1.60M
+214.37%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.03M
1.88%
+36.85K
+1.85%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.02M
1.87%
+241.77K
+13.57%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
WisdomTree BioRevolution Fund
0.4%
Global X Genomics & Biotechnology ETF
0.37%
Invesco Nasdaq Biotechnology ETF
0.04%
Fidelity Enhanced Small Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.77%
WisdomTree BioRevolution Fund
占比0.4%
Global X Genomics & Biotechnology ETF
占比0.37%
Invesco Nasdaq Biotechnology ETF
占比0.04%
Fidelity Enhanced Small Cap ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Biotechnology ETF
占比0.03%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
